Comparison of Cardiac Computed Tomographic Angiography (CTA) to Tc-99m Single Photon Emission Computed Tomography (SPECT)

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00449943

Enrollment

107

Registered

2007-03-21

Start date

2006-09-30

Completion date

2010-12-31

Last updated

2012-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

Cardiac Invasive Catheterization Angiography, Single Photon Emission Computed Tomography, Computed Tomography Angiography

Brief summary

Cardiovascular disease and ischemic heart disease is the #1 killer in Canada. Currently, Cardiac invasive catheterization angiography (CICA) is the gold standard for the assessment of the arteries in the heart. However, cardiac catheterization has risks which prohibit its use in all patients. These risks include: death, heart attack, stroke and bleeding. Cardiac computed tomography angiography (CTA) is a new non-invasive technology which may enable the evaluation of patients' coronary anatomy without exposing patients to the risks of invasive cardiac catheterization. The purpose of this project is to compare CT angiography (CTA) to Tc-99m single photon emission computed tomography (Tc-99m SPECT) We will enroll patients who are waiting for a CICA or who have been referred for a TC-99m SPECT or CTA scans at the University of Ottawa Heart Institute. Consenting patients who are waiting for a CICA will have both a CTA and a Tc-99m SPECT scan. Consenting patients referred for a CTA or Tc-99m SPECT will have both the CTA and Tc-99m SPECT in a random order but not CICA (unless ordered by your physician).

Interventions

PROCEDUREComputed Tomographic Angiography

CT scan

PROCEDUREMyocardial Perfusion Imaging Scan

SPECT

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients referred for Tc-99m SPECT or CTA; or * Patients referred for CICA without preceding (\< 12 months) MPI or CTA

Exclusion criteria

* Previous revascularization (PCI or CABG) * Age \< 18 years or lack of consent * Renal Insufficiency (GFR \< 60 ml/min) * Allergy or contraindication to contrast agent or dipyridamole * Refractory angina requiring urgent/emergent coronary angiography * Contraindication to radiation exposure (e.g. pregnancy) * Uncontrolled HR * Atrial fibrillation, frequent atrial or ventricular ectopy (\> 1/minute) * Unable to perform 10 second breath-hold

Design outcomes

Primary

Measure	Time frame
To measure the accuracy of CTA to SPECT for the diagnosis of CAD	1 year

Secondary

Measure	Time frame
To examine the accuracy of CTA predicting the mode of treatment: Medical therapy or revascularization (PCI versus CABG)	1 year

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026